**Title Page**

**The Risk of Stroke after Acute Myocardial Infarction in Patients with and without Atrial fibrillation: A Nationwide Cohort Study in Taiwan**

Cheng-Hung Chiang, MDa,b, Wan-Ting Hung, MDc, Wei-Chun Huang, MD, PhDb,c,d,e, Kun-Chang Lin, MD c, Chin-Chang Cheng, MDa,b, Feng-Yu Kuo, MDa

aCardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan

bSchool of Medicine, National Yang-Ming University, Taipei City, Taiwan

cDepartment of Critical Care Medicine, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan

dDepartment of Physical Therapy, Fooyin University, Kaohsiung City, Taiwan

eGraduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan

**Corresponding authors:**

Wei-Chun Huang, MD, PhD; e-mail: wchuanglulu@gmail.com

Department of Critical Care Medicine, Kaohsiung Veterans General Hospital, No. 386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City 81362, Taiwan

Tel: 886-7-3468278; Fax: 886-7-3455045

**Supplemental Table 1.** ICD-9-CM Code Used for Diagnosis in This Study

**Diagnosis ICD-9-CM code**

|  |  |
| --- | --- |
| ST elevated myocardial infarction | 410.0 to 410.6 or 410.9 |
| Non-ST elevated myocardial infarction | 410.7 or 410.8 |
| Stroke and transient ischemic attack | 430 to 437 or A290 to A294 |
| Hypertension | 401 to 405 |
| Diabetes | 250 |
| Heart failure | 428 |
| Dyslipidemia | 272 |
| Chronic obstructive pulmonary disease | 491, 492 or 496 |
| End-stage renal disease | 585 |
| Percutaneous coronary intervention | Procedure codes 36.0, 36.01, 36.02, 36.05, 36.06, or 36.09 |
| Coronary artery bypass graft | Procedure codes 36.10 to 36.19 |

**Supplemental Table 2.** CHA2DS2-VASc score and medications of patients with first hospitalized AMI with and without AF

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Without AF (N=8,530) | With AF (N=8,530) | P-value |
| CHA2DS2-VASc score |
|  1 | 625(7.33%) | 641(7.51%) | <.0001 |
|  2 | 1335(15.65%) | 1378(16.15%) |  |
|  3 | 2190(25.67%) | 2137(25.05%) |  |
|  4 | 2336(27.39%) | 2437(28.57%) |  |
|  5 | 1489(17.46%) | 1533(17.97%) |  |
|  ≥6 | 555(6.51%) | 404(4.74%) | 　 |
| Medications |
|  Aspirin | 6649(77.95%) | 7072(82.91%) | <.0001 |
|  Clopidogrel | 5062(59.34%) | 5487(64.33%) | <.0001 |
|  ACEI/ARB | 5075(59.5%) | 5683(66.62%) | <.0001 |
|  Beta Blocker | 4125(48.36%) | 4540(53.22%) | <.0001 |
|  Statin | 2764(32.4%) | 2610(30.6%) | 0.0111 |
|  Warfarin | 176(2.06%) | 1046(12.26%) | <.0001 |
|  Class I AAD | 0(0%) | 3(0.04%) | 0.25 |
|  Class III AAD | 730(8.56%) | 3203(37.55%) | <.0001 |
|  Digoxin | 699(8.19%) | 2321(27.21%) | <.0001 |
|  Non-dihydropyridine CCB | 1010(11.84%) | 1831(21.47%) | <.0001 |

*ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *AAD* antiarrhythmic drug, *CCB* calcium-channel blocker

**Supplemental Table 3.** CHA2DS2-VASc score and medications in patients with new onset AF during admission and with preexisting AF before admission

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | New onset AF during admission(N=6,641) | Preexisting AF before admission(N=1,889) | P value |
| CHA2DS2-VASc score |  |  |  |
| 1 | 554(8.34%) | 87(4.61%) | <.0001 |
| 2 | 1135(17.09%) | 243(12.86%) |  |
| 3 | 1654(24.91%) | 483(25.57%) |  |
| 4 | 1820(27.41%) | 617(32.66%) |  |
| 5 | 1172(17.65%) | 361(19.11%) |  |
| ≥6 | 306(4.61%) | 98(5.19%) | 　 |
| Medications |  |  |  |
| Aspirin | 5583(84.07%) | 1489(78.82%) | <.0001 |
| Clopidogrel | 4243(63.89%) | 1244(65.85%) | 0.1159 |
| ACEI/ARB | 4436(66.8%) | 1247(66.01%) | 0.5241 |
| Beta Blocker | 3553(53.5%) | 987(52.25%) | 0.3363 |
| Statin | 2055(30.94%) | 555(29.38%) | 0.1932 |
| Warfarin | 675(10.16%) | 371(19.64%) | <.0001 |
| Class I AAD | 3(0.05%) | 0(0%) | 1 |
| Class III AAD | 2686(40.45%) | 517(27.37%) | <.0001 |
| Digoxin | 1677(25.25%) | 644(34.09%) | <.0001 |
| Non-dihydropyridine CCB | 1394(20.99%) | 437(23.13%) | 0.0453 |

*ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *AAD*